ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Rallybio Corporation to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 24, 2021 GMT

NEW HAVEN, Conn.--(BUSINESS WIRE)--Nov 24, 2021--

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 8:00 a.m. ET. Rallybio will also host one-on-one meetings on the same day.

A webcast of the presentation will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.

ADVERTISEMENT

About Rallybio

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20211124005492/en/

CONTACT: Investor Contacts

Steven Tuch

investors@rallybio.comHannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.comMedia Contact

Tara DiMilia

908-369-7168

Tara.dimilia@tmstrat.com

KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH CLINICAL TRIALS OTHER HEALTH

SOURCE: Rallybio Corporation

Copyright Business Wire 2021.

PUB: 11/24/2021 08:00 AM/DISC: 11/24/2021 08:02 AM

http://www.businesswire.com/news/home/20211124005492/en